OYEN, Willem Jozef Gerard
 Distribuzione geografica
Continente #
NA - Nord America 43.235
AS - Asia 21.513
EU - Europa 5.707
SA - Sud America 2.947
AF - Africa 1.244
Continente sconosciuto - Info sul continente non disponibili 243
OC - Oceania 60
Totale 74.949
Nazione #
US - Stati Uniti d'America 42.591
SG - Singapore 15.503
BR - Brasile 2.475
CN - Cina 2.127
VN - Vietnam 1.974
FI - Finlandia 1.375
IE - Irlanda 1.067
NG - Nigeria 917
FR - Francia 648
DE - Germania 632
IT - Italia 494
HK - Hong Kong 451
NL - Olanda 415
GB - Regno Unito 402
CA - Canada 385
IN - India 262
TR - Turchia 179
BD - Bangladesh 176
AR - Argentina 167
IQ - Iraq 130
MX - Messico 127
RU - Federazione Russa 116
SE - Svezia 114
IL - Israele 106
ZA - Sudafrica 93
PK - Pakistan 90
ES - Italia 69
PL - Polonia 67
JP - Giappone 61
UA - Ucraina 59
CO - Colombia 57
VE - Venezuela 56
EC - Ecuador 53
CL - Cile 52
MA - Marocco 50
ID - Indonesia 47
AU - Australia 45
KE - Kenya 45
UZ - Uzbekistan 45
SA - Arabia Saudita 42
JO - Giordania 34
TN - Tunisia 31
AE - Emirati Arabi Uniti 30
EG - Egitto 30
IR - Iran 30
PH - Filippine 30
PY - Paraguay 29
RO - Romania 28
DZ - Algeria 27
MY - Malesia 26
JM - Giamaica 25
CZ - Repubblica Ceca 24
NP - Nepal 23
AT - Austria 22
AZ - Azerbaigian 22
BO - Bolivia 21
PE - Perù 20
OM - Oman 19
CR - Costa Rica 17
KZ - Kazakistan 17
MD - Moldavia 17
DO - Repubblica Dominicana 16
LB - Libano 16
BE - Belgio 15
CH - Svizzera 15
UY - Uruguay 15
GR - Grecia 14
LT - Lituania 14
SN - Senegal 14
A2 - ???statistics.table.value.countryCode.A2??? 13
NZ - Nuova Zelanda 13
PA - Panama 13
AL - Albania 12
HN - Honduras 12
PT - Portogallo 12
ET - Etiopia 11
PS - Palestinian Territory 11
RS - Serbia 11
DK - Danimarca 9
TT - Trinidad e Tobago 9
GT - Guatemala 8
NI - Nicaragua 8
BH - Bahrain 7
BY - Bielorussia 7
HU - Ungheria 7
QA - Qatar 7
SY - Repubblica araba siriana 7
BG - Bulgaria 6
HR - Croazia 6
KR - Corea 6
NO - Norvegia 6
SV - El Salvador 6
BB - Barbados 5
CI - Costa d'Avorio 5
PR - Porto Rico 5
XK - ???statistics.table.value.countryCode.XK??? 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
GD - Grenada 4
GE - Georgia 4
Totale 74.648
Città #
Chandler 7.379
Singapore 7.309
Wilmington 6.856
San Mateo 2.586
The Dalles 2.292
Ashburn 1.755
Ann Arbor 1.402
Shanghai 1.383
Helsinki 1.373
Leawood 1.222
Princeton 1.121
Lawrence 1.117
San Jose 1.087
Dublin 1.062
Boardman 1.009
Benin City 911
Fairfield 685
New York 674
Woodbridge 650
Ho Chi Minh City 638
Dallas 633
Paris 576
Hanoi 532
Hong Kong 408
Amsterdam 394
Seattle 375
San Diego 328
Beijing 326
London 247
Santa Clara 232
Toronto 220
Los Angeles 215
São Paulo 214
Milan 202
Norwalk 132
Da Nang 108
Kocaeli 103
Haiphong 88
Rio de Janeiro 85
Falkenstein 80
Brooklyn 78
Phoenix 76
Belo Horizonte 71
Chicago 68
Houston 63
Rome 60
Montreal 55
Warsaw 55
Orem 48
Baghdad 47
Tokyo 47
Johannesburg 45
Buffalo 44
Dhaka 43
Brasília 42
Pune 41
Tashkent 41
Porto Alegre 39
Moscow 38
Miami 37
Stockholm 37
Reston 36
Boston 34
Nairobi 34
Hải Dương 33
Council Bluffs 32
Campinas 31
Chennai 31
Hillsboro 31
Monmouth Junction 31
Philadelphia 31
Atlanta 30
Des Moines 30
Munich 30
Amman 29
Biên Hòa 29
Curitiba 29
Las Vegas 29
Redmond 29
Mexico City 28
Charlotte 27
Frankfurt am Main 26
San Francisco 26
Istanbul 24
Manchester 24
Queens 24
Naples 22
Ribeirão Preto 22
Salvador 22
Lahore 21
Can Tho 20
Erbil 20
Fortaleza 20
New Delhi 20
Quito 20
Columbus 19
Guarulhos 19
Asunción 18
Buenos Aires 18
Denver 18
Totale 50.101
Nome #
(18)FDG-PET for staging (non)seminomatous germ cell tumours [(N)SGCT] and for evaluation of postchemotherapy residual masses. 126
18-F fluorodeoxygenase (FDG) positron emission tomography (PET) scanning prior to radical lung radiotherapy. A retrospective audit of practice 121
2-(F-18)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: A prospective study 119
Procedure guidelines for PET/CT tumour imaging with Ga-68-DOTA-conjugated peptides: Ga-68-DOTA-TOC, Ga-68-DOTA-NOC, Ga-68-DOTA-TATE 116
18F-FDG-PET reduces the number of direct laryngoscopies in patients with suspected recurrent laryngeal carcinoma after radiotherapy 114
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 112
[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer 108
Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients 106
Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor 105
[18F]FDG PET/CT in Large Vessel Vasculitis: The Impact of Expertise and Confounders on Image Analysis 104
7TH ANNUAL-MEETING OF THE INTERNATIONAL RESEARCH GROUP IN IMMUNOSCINTIGRAPHY AND IMMUNOTHERAPY 103
18F-FLT-PET for the evaluation of MEK inhibitor AZD6244 101
F-18-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation 101
F-18-FDG PET/CT for the Detection of Septic Embolisms in Patients with Infectious Endocarditis 100
Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss 99
F-18-FDG PET/CT for Detection of Metastatic Infection in Gram-Positive Bacteremia 99
The Role of FDG-PET in the Assessment of Thyroid Nodules with an Indeterminant or Suspicious Cytologic Diagnosis 98
[F-18]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma 98
[F-18]-Fluorination of a Leukotriene B4 Receptor Antagonist via Hydrazone Formation and its Application in Infection Imaging 98
F-18-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality 98
3 '-Deoxy-3 '-F-18-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients 98
Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success 97
F-18-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis 97
18F-FDG PET/CT in Detecting Metastatic Infection in Children 97
Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-68-DOTA-conjugated somatostatin receptor targeting peptides and F-18-DOPA 96
Effect of the positron range on the spatial resolution of a new generation pre-clinical PET using fluorine-18, gallium-68, zirconium-89 and iodine-124 96
A direct comparison of four different Ga-68-labeled RGD peptides for PET/CT imaging of angiogenesis 96
F-18-FDG PET AS A PREDICTOR OF PULMONARY FUNCTION IN SARCOIDOSIS 96
Kidney protection during peptide receptor radionuclide therapy (PRRT) 95
F-18-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients 95
Improved selection of patients for hepatic surgery of colorectal liver metastases with FDG-PET: A randomized study 95
[F-18]fluoro-2-deoxy-d-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic e-cadherin mutation carrier 95
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 95
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems 94
Background-subtracted optimal threshold segmentation algorithm for FDG-PET based GTV delineation: Theory and experimental validation 94
99mTc-interleukin-8 for imaging acute osteomyelitis 94
Radiation Exposure (Un)Awareness amongst nuclear medicine patients - a systematic review 94
PET-CT for response assessment and treatment adaptation in head and neck cancer 93
In-111-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib 93
A 3-step pretargeting strategy to image infection 93
New targeted probes for radioimaging of angiogenesis 92
F-18-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors 92
Pretargeted immuno-PET imaging and radioimmunotherapy of prostate cancer with an anti-EGP1 x anti-HSG bispecific antibody 92
FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma 92
Imaging of cellular therapies 92
A bivalent leukotriene B-4 antagonist for scintigraphic Imaging of infectious foci 92
In-111-anti-F4/80 for in vivo tracking of tumor associated macrophages 92
Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo 91
Radioimmunotherapy with I-131-cG250 monoclonal antibody in patients with metastasized RCC, a phase I/II study. 91
FDG-PET in diagnosing central venous catheter related infection in stem cell transplant recipients 91
F-18-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis 91
The role of megalin in the renal uptake of radiolabeled peptides 90
F-18-FDG PET of thyroid nodules with inconclusive cytologic results - Reply 90
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer 90
F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection 90
Comparison of liver SUV using unenhanced CT versus contrast- enhanced CT for attenuation correction in 18 F-FDGPET/CT 89
FDG-PET and CT in the staging of melanoma patients with lymph node metastases; diagnostic performance and clinical consequences 89
Clinical application of FDG-PET/CT in metastatic infections 89
Validated image fusion of dedicated PET and CT for external beam radiation therapy in the head and neck area 89
SPECT/CT-based Dosimetry for a Multicentre Trial of Selumetinib Enhanced Radioiodine Treatment of Differentiated Thyroid Cancer: Preliminary Results 88
INTERIM ANALYSIS OF A PHASE I RADIOIMMUNOTHERAPY STUDY IN ADVANCED RENAL CELL CARCINOMA PATIENTS USING LUTETIUM-177 LABELED MONOCLONAL ANTIBODY CG250 88
SORAFENIB REDUCES UPTAKE OF 111-INDIUM LABELED BEVACIZUMAB IN CLEAR CELL RENAL CELL CARCINOMA 88
Progress in nuclear medicine procedures in head and neck oncology 88
Zirconium-89-girentuximab PET/CT imaging in renal cell carcinoma: first in man results 88
EANM Focus 1: one small step for two men, one giant leap for a specialty 88
PET and SPECT imaging of rheumatoid arthritis with radiolabeled anti-FAP antibody correlates with severity of arthritis 88
Ga-68-labelled exendin-3, a new agent for the detection of insulinomas with PET 88
Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma 87
Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody 87
A PHASE IB CLINICAL STUDY WITH 18F-FDG-PET RESPONSE EVALUATION OF THE COMBINATION OF TEMSIROLIMUS (T) AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN BREAST, ENDOMETRIAL AND OVARIAN CANCER 86
PET/CT with C-11-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data 86
IMPROVED SELECTION OF PATIENTS FOR HEPATIC SURGERY OF COLORECTAL LIVER METASTASES WITH FDG-PET: RESULTS OF THE RANDOMIZED DUTCH POLEM STUDY 85
Molecular imaging of hypoxia 85
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer 85
Evaluation of the advanced ReSPECT image reconstruction software in a phantom model and in parathyroid scanning 85
Megalin Plays an Important Role in the Renal Uptake of Various Radiolabeled Peptides: Studies in Megalin-Deficient Mice 85
F-18-FDG PET in detecting metastatic infectious disease 85
Tumor segmentation and quantitative assessment of glucose metabolism for different histological types of NSCLC using dynamic F-18-FDG PET 85
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes 85
F-18-fluorodeoxyglucose positron emission tomography of colonic anastomosis: A possibility to detect anastomotic leakage? A pilot study 85
EANM commitment towards involvement and engagement of patients and the public: learning from the UK experience 85
Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer 84
Albumin derived peptides efficiently reduce renal uptake of radiolabeled peptides 84
Radiopharmaceuticals to image infection and inflammation 84
WHICH FACTORS PREDICT THE RESULTS OF PITUITARY SURGERY IN ACROMEGALY 84
Consensus on molecular imaging and theranostics in prostate cancer 84
F-18-2-Deoxy-2-fluoro-D-glucose Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging for the Detection of Experimental Colorectal Liver Metastases 84
In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging 83
A modelling approach to estimate the FDG arterial plasma time activity curve in Patlak-based therapy response analysis 83
Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise 83
Pulmonary sclerosing hemangioma detected by fluorodeoxyglucose positron emission tomography in familial adenomatous polyposis: Report of a case 83
Dynamic FDG PET in liver metastases of colorectal cancer: repeatability of dynamic and static FDG PET parameters. 83
Alpha- versus beta-emitting particles for pretargeted radioimmunotherapy of CEA-expressing human colon cancer xenografts 83
Evaluation of a Ga-68-labelled Minigastrin for PET Imaging of CCK2/gastrin Receptor-Positive Tumours 82
SPECIFIC ANTIBODY UPTAKE IN TUBERCULOSIS 82
Quantitative Assessment of Heterogeneity in Tumor Metabolism Using FDG-PET 82
CAN FOG-PET PREDICT RADIATION TREATMENT OUTCOME IN HEAD AND NECK CANCER? 82
Radioimmunotheapy with [I-131]cG250 in patients with metastasized renal cell cancer: Dosimetric analysis and immunologic response 82
STERICALLY STABILIZED LIPOSOMES LABELED WITH IN-111 TO IMAGE FOCAL INFECTION 82
Pretargeted immunoPET for imaging human colonic cancer in a mouse model 82
Totale 9.229
Categoria #
all - tutte 561.150
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 561.150


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.548 0 16 98 1.389 3 6 125 846 434 329 1.015 287
2022/202317.903 2.481 628 1.666 1.827 1.928 1.633 9 1.746 3.329 1.396 999 261
2023/20246.755 651 912 1.757 185 208 613 138 381 91 69 490 1.260
2024/20259.716 186 155 58 29 29 1.005 486 1.576 1.297 2.812 936 1.147
2025/202621.791 3.861 1.005 381 1.706 576 757 9.033 1.435 1.268 975 229 565
2026/20271.982 631 1.351 0 0 0 0 0 0 0 0 0 0
Totale 74.949